FDA approves Merck cancer drug

Merck also announced that the Food and Drug Administration gave breakthrough therapy designation to Keytruda for advanced non-small cell lung cancer that has progressed on or following platinum-based chemotherapy. The designation is intended to speed the approval process for drugs that treat diseases that have no or inadequate treatments. The company earned $895 million, or 31 cents a share, during the July-September quarter. A year earlier it earned $1.12 billion, or 38 cents a share.

Read the source article at USA TODAY

About the Author

Leave a Reply